Abdou Y Omorou1,2,3, Hamza Achit4, Maud Wieczorek5, Jacques Pouchot6, Bruno Fautrel7, Anne-Christine Rat5, Francis Guillemin4,5,8. 1. CHRU-Nancy, INSERM, CIC-Epidémiologie Clinique, Université de Lorraine, Nancy, France. y.omorou@chru-nancy.fr. 2. Université de Lorraine, APEMAC, Nancy, France. y.omorou@chru-nancy.fr. 3. National Clinical Research Platform for Quality of Life in Oncology, France, CHRU de Nancy, Nancy, France. y.omorou@chru-nancy.fr. 4. CHRU-Nancy, INSERM, CIC-Epidémiologie Clinique, Université de Lorraine, Nancy, France. 5. Université de Lorraine, APEMAC, Nancy, France. 6. Université Paris Descartes, APEMAC, Paris, France. 7. UPMC Université Paris 6, GRC-UPMC 08 (EEMOIS), Sorbonne Universités, Paris, France. 8. National Clinical Research Platform for Quality of Life in Oncology, France, CHRU de Nancy, Nancy, France.
Abstract
PURPOSE: To examine the respective and combined impact of "hypothetical" functional impairment (FI) and burden of comorbidities accrual on a 5-year risk of health utility (HU) loss in osteoarthritis (OA). METHODS: Participants of the Knee and Hip Osteoarthritis Long-term Assessment (KHOALA) study with a 5-year follow-up were included. FI, number of comorbidities and HU were measured annually by the WOMAC, Functional Comorbidity Index and Short-Form 6D, respectively. We estimated the population risk of HU loss (PRD: population risk difference, PRR: population risk ratio) under hypothetical FI and comorbidities using the parametric G-formula. Then, mediation analysis investigated the causal mechanism of comorbidities on HU through FI by estimating total, direct and indirect effects. RESULTS: We examined data from 767 patients (68.8% women; 61.6 years). The estimated 5-year risk of HU loss was 47.5% [41.9; 52.2] under natural course and 24.9% [15.5; 34.2] when imposing "Patient acceptable function and No comorbidity" corresponding to a PRD = - 22.6 [- 26.5; - 21.2] and a PRR = 0.5 [0.4; 0.6]. The estimated total risk of HU loss comparing "Two comorbidities" versus "No comorbidity" was significant without mediation effect of FI: Total = 10.1% [6.8; 12.9]; direct = 8.0% [2.7; 13.1]; indirect = 2.1% [- 2.0; 5.2]. CONCLUSIONS: FI and comorbidities are important and independent determinants of HU loss in patient with OA. Half of cases (50%) of HU loss during 5 years could be avoided by preventing comorbidities (30%) and limiting FI under patient acceptable function (20%). Caregivers should additionally pay close attention to the prevention and the treatment of comorbidities in routine management of OA.
PURPOSE: To examine the respective and combined impact of "hypothetical" functional impairment (FI) and burden of comorbidities accrual on a 5-year risk of health utility (HU) loss in osteoarthritis (OA). METHODS:Participants of the Knee and Hip Osteoarthritis Long-term Assessment (KHOALA) study with a 5-year follow-up were included. FI, number of comorbidities and HU were measured annually by the WOMAC, Functional Comorbidity Index and Short-Form 6D, respectively. We estimated the population risk of HU loss (PRD: population risk difference, PRR: population risk ratio) under hypothetical FI and comorbidities using the parametric G-formula. Then, mediation analysis investigated the causal mechanism of comorbidities on HU through FI by estimating total, direct and indirect effects. RESULTS: We examined data from 767 patients (68.8% women; 61.6 years). The estimated 5-year risk of HU loss was 47.5% [41.9; 52.2] under natural course and 24.9% [15.5; 34.2] when imposing "Patient acceptable function and No comorbidity" corresponding to a PRD = - 22.6 [- 26.5; - 21.2] and a PRR = 0.5 [0.4; 0.6]. The estimated total risk of HU loss comparing "Two comorbidities" versus "No comorbidity" was significant without mediation effect of FI: Total = 10.1% [6.8; 12.9]; direct = 8.0% [2.7; 13.1]; indirect = 2.1% [- 2.0; 5.2]. CONCLUSIONS: FI and comorbidities are important and independent determinants of HU loss in patient with OA. Half of cases (50%) of HU loss during 5 years could be avoided by preventing comorbidities (30%) and limiting FI under patient acceptable function (20%). Caregivers should additionally pay close attention to the prevention and the treatment of comorbidities in routine management of OA.
Entities:
Keywords:
Comorbidities; Functional impairment; Health utility; Lower-limb osteoarthritis
Authors: Francis Guillemin; Anne-Christine Rat; Christian H Roux; Bruno Fautrel; Bernard Mazieres; Xavier Chevalier; Liana Euller-Ziegler; Patrice Fardellone; Evelyne Verrouil; Johanne Morvan; Jacques Pouchot; Joel Coste; Alain Saraux Journal: Joint Bone Spine Date: 2012-06-20 Impact factor: 4.929
Authors: Alexander P Keil; Jessie K Edwards; David B Richardson; Ashley I Naimi; Stephen R Cole Journal: Epidemiology Date: 2014-11 Impact factor: 4.822
Authors: J H Salmon; A C Rat; J Sellam; M Michel; J P Eschard; F Guillemin; D Jolly; B Fautrel Journal: Osteoarthritis Cartilage Date: 2016-03-23 Impact factor: 6.576
Authors: F Guillemin; A C Rat; B Mazieres; J Pouchot; B Fautrel; L Euller-Ziegler; P Fardellone; J Morvan; C H Roux; E Verrouil; A Saraux; J Coste Journal: Osteoarthritis Cartilage Date: 2011-08-16 Impact factor: 6.576
Authors: N E Lankhorst; J Damen; E H Oei; J A N Verhaar; M Kloppenburg; S M A Bierma-Zeinstra; M van Middelkoop Journal: Osteoarthritis Cartilage Date: 2016-12-09 Impact factor: 6.576
Authors: F Tubach; P Ravaud; G Baron; B Falissard; I Logeart; N Bellamy; C Bombardier; D Felson; M Hochberg; D van der Heijde; M Dougados Journal: Ann Rheum Dis Date: 2004-05-06 Impact factor: 19.103
Authors: Kossar Hosseini; Cécile Gaujoux-Viala; Joel Coste; Jacques Pouchot; Bruno Fautrel; Anne-Christine Rat; Francis Guillemin Journal: Best Pract Res Clin Rheumatol Date: 2012-10 Impact factor: 4.098